Nektar Explores Six-Month Eczema Dosing For Patients With Deep, Sustained Responses
Treatment-withdrawal results due in the first quarter of 2027 will help test how long the experimental drug's benefits last.
Nektar Therapeutics, which develops experimental medicines that alter immune responses, is exploring eczema injections as infrequent as every six months for patients with deep, sustained responses after 52 weeks of treatment. Chief Medical Officer Dr. Mary Tagliaferri outlined the possibility on Thursday's earnings call, ahead of treatment-withdrawal results expected in the first quarter of 2027.
The Durability Bar Against Dupixent
Nektar is testing whether rezpegaldesleukin can keep eczema under control with longer gaps between injections. The company is developing the drug for autoimmune and chronic inflammatory diseases; its approach aims to expand regulatory immune cells that help control inflammation.
Tagliaferri cited a Dupixent withdrawal study in which approximately 50% of patients retained at least a 75% improvement on an eczema severity measure after nine months. Matching or exceeding that retention at 12 months would be "an interesting finding," she said.
The upcoming analysis follows 125 patients who completed initial and maintenance treatment: 110 previously received rezpegaldesleukin and 15 received placebo. Keeping the placebo group in follow-up preserved patients' uncertainty about their original treatment assignments.
Patients received no injections during follow-up. Researchers assessed skin improvement, itch and quality of life at weeks 4, 13, 26, 39 and 52 after treatment stopped.
Responding to a question from an analyst at B. Riley about differentiation, Tagliaferri said, "Our objective is to give patients a more convenient and flexible dosing schedule after an initial treatment period."
Quarterly Dosing Offers An Earlier Clue
Earlier eczema results give management a starting point: 83% of patients receiving quarterly maintenance injections retained at least a 75% improvement in eczema severity. Tagliaferri said that group received just three maintenance doses, and some patients' responses continued to deepen.
Alopecia areata, an autoimmune hair-loss condition, supplied another durability test. Among eight patients who reached a hair-loss severity score of 20 or less after 52 weeks of treatment, six maintained that response after four months without treatment and five after six months—75% and 63%, respectively.
The share reaching a score of 10 or less rose to 19% after six months off treatment, from 7% when treatment ended. Management sees the eczema and alopecia findings as grounds for testing less frequent injections; the six-month eczema schedule remains a possibility for selected responders.
Cash Backs The Late-Stage Trials
Nektar has begun all three late-stage eczema trials, with initial results expected in summer 2028 and an FDA approval application targeted for 2029. The trials will test monthly and quarterly maintenance dosing after a 24-week initial treatment period. Its late-stage alopecia trial is scheduled to start in December.
Chief Financial Officer Linda Rubinstein raised the year-end cash-and-investments outlook on Thursday's call to more than $840 million, from $815 million–$840 million. The company ended September with $952.9 million, compared with $245.8 million at the end of 2025, and Rubinstein said it had no debt.
Research and development spending rose to $44.1 million in the third quarter from $27.3 million a year earlier. Nektar attributed the increase primarily to late-stage trial preparations and manufacturing work for rezpegaldesleukin.
The first-quarter 2027 withdrawal results will provide the next evidence on whether eczema responses persist long enough to support wider gaps between treatments.
Sources
- Nektar Therapeutics results release (Form 8-K, EX-99.1) — SEC EDGAR
- Nektar Therapeutics Announces Third Quarter 2026 Financial Results — prnewswire.com
- Nektar Therapeutics to Participate in Two Investor Conferences in November — prnewswire.com